Free Trial
NYSEAMERICAN:ASXC

Asensus Surgical (ASXC) Stock Price, News & Analysis

$0.24
0.00 (-1.39%)
(As of 05/24/2024 08:49 PM ET)
Today's Range
$0.24
$0.25
50-Day Range
N/A
52-Week Range
$0.20
$0.65
Volume
1.01 million shs
Average Volume
1.41 million shs
Market Capitalization
$65.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$0.68

Asensus Surgical MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
180.1% Upside
$0.68 Price Target
Short Interest
Bearish
6.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.48mentions of Asensus Surgical in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.24) to ($0.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.55 out of 5 stars

ASXC stock logo

About Asensus Surgical Stock (NYSEAMERICAN:ASXC)

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

ASXC Stock Price History

ASXC Stock News Headlines

Asensus Surgical earnings: here's what Wall Street expects
Asensus Surgical Agrees To Karl Storz's Acquisition Offer; Stock Up
ASXC Oct 2024 0.500 put
Asensus Surgical Earnings Preview
Recap: Asensus Surgical Q4 Earnings
See More Headlines
Receive ASXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Asensus Surgical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/14/2024
Today
5/26/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:ASXC
CIK
N/A
Employees
207
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$0.68
High Stock Price Target
$1.00
Low Stock Price Target
$0.35
Potential Upside/Downside
+180.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-78,430,000.00
Net Margins
-902.25%
Pretax Margin
-899.16%

Debt

Sales & Book Value

Annual Sales
$8.58 million
Book Value
$0.05 per share

Miscellaneous

Free Float
264,516,000
Market Cap
$65.63 million
Optionable
Not Optionable
Beta
1.42
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Anthony  FernandoMr. Anthony Fernando (Age 52)
    President, CEO & Director
    Comp: $901.03k
  • Mr. Shameze Rampertab B.Sc. MBA (Age 57)
    CA, CPA, Executive VP & CFO
    Comp: $511.25k
  • Mr. Joshua B. Weingard (Age 51)
    Chief Legal Officer & Secretary
  • Mr. Paul Ziegler Jr. (Age 50)
    J.D., Vice President of Sales
  • Mr. Ethan Loiselle
    Vice President of Global Marketing
  • Ms. Amanda Owens
    Vice President of People
  • Mr. Ravi Kommineni
    Head of Global Quality & Regulatory
  • Mr. Motti Frimer
    Vice President of R&D, Digital Solutions and MD of Asensus Surgical

ASXC Stock Analysis - Frequently Asked Questions

Should I buy or sell Asensus Surgical stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Asensus Surgical in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ASXC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASXC, but not buy additional shares or sell existing shares.
View ASXC analyst ratings
or view top-rated stocks.

What is Asensus Surgical's stock price target for 2024?

2 equities research analysts have issued 1-year price targets for Asensus Surgical's shares. Their ASXC share price targets range from $0.35 to $1.00. On average, they anticipate the company's stock price to reach $0.68 in the next year. This suggests a possible upside of 180.1% from the stock's current price.
View analysts price targets for ASXC
or view top-rated stocks among Wall Street analysts.

Are investors shorting Asensus Surgical?

Asensus Surgical saw a decline in short interest in April. As of April 15th, there was short interest totaling 16,510,000 shares, a decline of 7.0% from the March 31st total of 17,750,000 shares. Based on an average daily volume of 1,580,000 shares, the days-to-cover ratio is currently 10.4 days. Approximately 6.2% of the company's stock are short sold.
View Asensus Surgical's Short Interest
.

How were Asensus Surgical's earnings last quarter?

Asensus Surgical, Inc. (NYSEAMERICAN:ASXC) released its earnings results on Tuesday, May, 14th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.02. The firm earned $1.12 million during the quarter, compared to analyst estimates of $1.10 million. Asensus Surgical had a negative net margin of 902.25% and a negative trailing twelve-month return on equity of 184.10%.

Who are Asensus Surgical's major shareholders?

Asensus Surgical's stock is owned by many different institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrea Biffi, Anthony C J Fernando, David Bruce Milne, Elizabeth Kwo and William N Starling Jr.
View institutional ownership trends
.

How do I buy shares of Asensus Surgical?

Shares of ASXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:ASXC) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners